Clinical bottom line
Nanotechnology-based drug delivery systems are rapidly advancing the treatment of ocular diseases, particularly those affecting the posterior segment, by enhancing drug bioavailability, targeting, and sustained release. These innovations promise to overcome limitations of conventional therapies such as poor ocular penetration and frequent dosing. Early clinical and preclinical data indicate improved therapeutic efficacy and reduced side effects with nanoparticle carriers, liposomes, and exosome-based platforms. However, translation to routine clinical practice awaits further validation of long-term safety, standardized manufacturing, and regulatory approval (Wu et al., 2024; Li et al., 2023).
What the evidence shows
Wu et al. (2024) provide a detailed review of innovative nanotechnology applications in drug delivery for posterior segment ocular diseases, highlighting advances in biodegradable nanoparticles and stimuli-responsive systems that enable controlled, sustained drug release directly to retinal tissues. Their analysis underscores improved pharmacokinetics and therapeutic outcomes in models of age-related macular degeneration and diabetic retinopathy.
Li et al. (2023) summarize recent progress in nanocarriers including polymeric nanoparticles, liposomes, and dendrimers, emphasizing enhanced corneal penetration and reduced systemic exposure. They discuss the potential of surface modifications to improve targeting and reduce immunogenicity.
Ahmed et al. (2023) offer a comprehensive overview of ocular drug delivery challenges and nanomedicine solutions, noting that nanotechnology facilitates overcoming ocular barriers such as the corneal epithelium and blood-retinal barrier, thereby increasing intraocular drug concentrations.
Lin et al. (2025) focus on nanomedicine-based ophthalmic systems, including nanoemulsions and nanogels, which have demonstrated promising results in preclinical and early clinical studies for glaucoma and uveitis by improving drug stability and patient compliance.
Emerging evidence also points to exosome-based delivery as a novel, biocompatible approach for targeted therapy with minimal toxicity, though clinical data remain limited (Li et al., 2023).
Caveats and uncertainty
Most data derive from preclinical studies or early-phase clinical trials with small sample sizes.
Long-term ocular and systemic safety profiles of various nanomaterials require further elucidation.
Manufacturing scalability and regulatory pathways for nanomedicines remain complex and evolving.
Variability in nanoparticle formulations and delivery routes complicates direct comparison and standardization.
Cost-effectiveness and patient acceptability have yet to be fully assessed.
How this may change practice
Nanotechnology-based delivery systems may reduce injection frequency and improve adherence in chronic ocular diseases requiring intravitreal therapy.
Enhanced targeting could minimize off-target effects and systemic exposure, improving safety profiles.
Clinicians should monitor emerging clinical trial data to identify approved nanomedicines suitable for integration into practice.
Multidisciplinary collaboration between ophthalmologists, pharmacologists, and nanotechnologists will be crucial for translation.
Patient education on novel delivery modalities will support acceptance and adherence.